Seeking Alpha

Seeking Alpha Portfolio App for iPad

2,141 people get CLDX articles and Market Currents by email alert.

Get email alerts on CLDX »

CLDX

Celldex Therapeutics, Inc

5/22/2013, 8:02 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 2, 12:26 PM Celldex Therapeutics (CLDX +1.8%) moves up today, despite missing on both its Q1 EPS and revenue numbers. The company posted a net loss of $17.3M, or $0.23 per share, compared to a net loss of $13.5M, or $0.27 per share a year earlier. Looking forward however, CEO Anthony Marucci comments that the company's on track to initiate accelerated approval of its CDX 011 breast cancer study later this year and remains pleased with the pace of enrollment in both its Phase 3 study in frontline glioblastoma, as well as its Phase 2 study in refractory glioblastoma. 1 Comment [Healthcare, Earnings, On the Move]
Thursday, May 2, 10:53 AM Celldex (CLDX): Q1 EPS of -$0.23 misses by $0.01. Revenue of $2.41M misses by $0.01M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, May 1, 3:24 PM A number of biotechs are sharply lower amid rumors of a sizable Bio-fund going out of business and liquidating its positions. It's Ayer Capital Management according to sources, reports Adam Feuerstein. (PCYC -5.6%), (CLDX -4.9%), (NPSP -3.1%), (HALO -3.8%). 6 Comments [Healthcare, On the Move]
Monday, April 8, 9:42 AM SAC Capital has increased its stake in Celldex Therapeutics (CLDX +0.5%) to 3.93M shares, or 4.88%, from the 2.7M shares that Steve Cohen's hedge fund held at the end of March. Comment! [Healthcare]
Friday, March 8, 1:43 PM Celldex (CLDX +12.6%) moves up today on a host of Street comments, regaining yesterday's losses and more after Roth Capital reiterates its Focus Stock ranking, while Cantor Fitzgerald raises its price target to $16 a share and Jefferies ups it to $15. Cantor expects the company to begin receiving revenues from its CDX-o11 and rindopepimut drug candidates in 2016, a year earlier than first anticipated, while Jefferies calls it "a compelling biotech play with 2 PIII and 3 PI/II candidates providing multiple shots on goal." Comment! [Healthcare, On the Move]
Thursday, March 7, 10:16 AM Celldex Therapeutics (CLDX) crumbles 11.4% after its Q4 EPS miss and earnings call (slides), which one Yahoo poster describes as disappointing, as "execs seemed confused, analysts unhappy." Net loss widens to $16.8M from $12.7M, primarily due to increased trial costs. As of Feb 28, Celldex had liquidity of $189M following a $114.1M fundraising. (PR) 1 Comment [Healthcare, On the Move, Earnings]
Thursday, March 7, 8:30 AM Northwest Biotherapeutics (NWBO +2%) expects to complete the enrollment of a 312-patient Phase III trial for its Glioblastoma multiforme brain cancer drug by Q1 or early Q2 next year. NW Bio says its recruitment is faster or more efficient than that for rival drugs, including for treatments from Celldex (CLDX), Immunocellular (IMUC) and Agenus (AGEN). (PR) 1 Comment [Healthcare]
Thursday, March 7, 8:16 AM Celldex Therapeutics (CLDX): Q4 EPS of -$0.27 misses by $0.02. Revenue of $3.65M beats by $1.2M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, March 7, 12:05 AM Notable earnings before Thursday’s open: ARQL, CIEN, CLDX, CNQ, CNSL, DANG, FGP, FLY, IQNT, JRCC, KR, NAV, NGPC, SFD, SRPT Comment! [Earnings]
Wednesday, March 6, 5:30 PM Notable earnings before Thursday’s open: ARQL, CIEN, CLDX, CNQ, CNSL, DANG, FGP, FLY, IQNT, JRCC, KR, NAV, NGPC, SFD, SRPT Comment! [Earnings]
Wednesday, March 6, 11:11 AM Celldex Therapeutics (CLDX +2.3%) moves up after being initiated by Leerink Swann with an Outperform rating and a price target of $18 a share. Leerink cites the strength of the drug developer's portfolio, saying 6 wholly owned clinical-stage biologics assets make its breadth rare among small and mid-cap biotech companies. The coverage also comes just a day before the company is expected to announce plans for a late stage study of CDX-011, a treatment for metastatic breast cancer - which should be a key catalyst for the stock. 2 Comments [Healthcare, On the Move]
Wednesday, February 27, 5:46 PM After-hours top gainers, as of 5:15 p.m.: BWC +9%. ARAY +4%. IDIX +4%. CLDX +3%. UAN +3%.
After-hours top losers: GRPN -25%. BSFT -23%. ANW -14%. VCRA -12%. JCP -9%. 3 Comments [On the Move]
Thursday, February 14, 12:44 PM Celldex (CLDX +5.2%) gains today as the company says its final results from its Phase 1 study of CDX-301 supports the initiation of a pilot study in hematopoietic stem cell transplantation later this year. Comment! [Healthcare, On the Move]
Wednesday, February 6, 9:35 AM Celldex (CLDX) prices an offering of 12M shares at $7.50 each and raises a gross $90M, above the $75M the company had planned to raise. The net proceeds are $84.3M, which Celldex plans to use to help fund trials. The firm could bring in even more money, as the offering has a 30-day green-shoe option of 1.8M shares. Celldex is +2.6% at $7.80. (PR) Comment! [On the Move, Healthcare]
Monday, February 4, 6:25 PM Celldex Therapeutics (CLDX) slips in the post session after announcing plans to sell $75M of stock in a secondary offering. All shares are being sold by the company, with Jefferies and Leerink Swann acting as joint book-running managers. Shares -3.4% AH. Comment! [Healthcare, On the Move]
Thursday, January 10, 3:44 PM Shares of Celldex Therapeutics (CLDX +4.3%) gain today on the back of positive comments out of Cantor, calling the stock one of its top sector picks for 2013. The firm says that company has a solid pipeline, and visibility should to increase this year, mitigating the stock's risk. The firm maintains a Buy rating on the shares, but raises its price target to $13 from $9. Comment! [Healthcare, On the Move]